Sign in

    Matthew Baer • Morgan Stanley

    Matthew Baer is an Executive Director and Equity Research Analyst at Morgan Stanley, specializing in the U.S. life sciences and diagnostics sectors. He covers leading companies such as Thermo Fisher Scientific, Agilent Technologies, Danaher Corporation, and Waters Corporation, and is noted for delivering highly ranked research reports and actionable investment recommendations. Recognized by platforms like TipRanks for a success rate consistently above 60% and robust average returns on stock calls, Baer has shaped institutional investment views since joining Morgan Stanley in 2015 after prior analyst experience at Goldman Sachs and sector-focused roles in equity research. He holds FINRA Series 7, 63, 86, and 87 licenses, underscoring his credentials as a trusted advisor to institutional clients in healthcare equities.

    Matthew Baer's questions to Allogene Therapeutics Inc (ALLO) leadership

    Matthew Baer's questions to Allogene Therapeutics Inc (ALLO) leadership • Q3 2024

    Question

    Matthew Baer inquired about patient retention strategies for the ALPHA3 trial, specifically asking why a patient randomized to the 'watch and wait' control arm would choose to remain in the study.

    Answer

    Dr. David Chang, President and CEO, explained that 'watch and wait' is the current standard of care, and patients in the trial receive the best available care. He noted that investigators are confident in their ability to retain patients. Furthermore, if a patient in the control arm progresses and seeks another treatment, this is captured as a primary 'event' for the study's event-free survival endpoint, thus maintaining the trial's integrity.

    Ask Fintool Equity Research AI